Brilaroxazine phase 3 completed

Medications
1

Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD

Investigators saw brilaroxazine 50 mg achieved a 10.1-point reduction compared to placebo (-23.9 vs -13.8; P < .001). They also saw significant reductions in positive (P < .001), negative (P = .003), negative marder symptoms (P = .002), PANSS social cognition (P < .001), excitement/agitation (P < .001), PSP (P < .001), and CGI-S (P < .001). Furthermore, brilaroxazine 15 mg was superior to placebo for all endpoints and significant for social cognition (P = .024) and PSP (P = .022).

5 Likes
2

The potency looks quite good, especially for a dopamine modulator. Side effects look good.
The company expects to start its final phase 3 trial in the next few months, assuming it has enough money.The company stock is priced quite low. I am hoping it gets approved.

2 Likes